Sacubitril/Valsartan for Heart Failure with Preserved Ejection Fraction: A Cost-Effectiveness Analysis from the Perspective of the Chinese Healthcare System-Reference-Cited by-同舟云学术

Sacubitril/Valsartan for Heart Failure with Preserved Ejection Fraction: A Cost-Effectiveness Analysis from the Perspective of the Chinese Healthcare System

Published:2023-03-28 Issue:4 Volume:43 Page:265-275
ISSN:1173-2563
Container-title:Clinical Drug Investigation
language:en
Short-container-title:Clin Drug Investig

Author:

Wang Zhe,Lou Yake,Wang Qi,Sun Min,Li Xiaonan,Wang Yinghui,Wang Yuehui^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s40261-023-01249-8.pdf

Reference44 articles.

1. Tomasoni D, Adamo M, Anker MS, von Haehling S, Coats AJS, Metra M. Heart failure in the last year: progress and perspective. ESC Heart Fail. 2020;7:3505–30. https://doi.org/10.1002/ehf2.13124.

2. Groenewegen A, Rutten FH, Mosterd A, Hoes AW. Epidemiology of heart failure. Eur J Heart Fail. 2020;22:1342–56.

3. Kennel PJ, Kneifati-Hayek J, Bryan J, Banerjee S, Sobol I, Lachs MS, et al. Prevalence and determinants of Hyperpolypharmacy in adults with heart failure: an observational study from the National Health and Nutrition Examination Survey (NHANES). BMC Cardiovasc Disord. 2019;19:76. https://doi.org/10.1186/s12872-019-1058-7.

4. Jessup M, Brozena S. Heart failure. N Engl J Med. 2003;348:2007–18. https://doi.org/10.1056/NEJMra021498.

5. Wang H, Chai K, Du MH, Wang SF, Cai JP, Li YY, et al. Prevalence and incidence of heart failure among urban patients in China: a national population-based analysis. Circ Heart Fail. 2021;14:1127–35. https://doi.org/10.1161/CIRCHEARTFAILURE.121.008406.

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Dapagliflozin versus sacubitril–valsartan for heart failure with mildly reduced or preserved ejection fraction;Frontiers in Pharmacology;2024-03-19

2. Cost-effectiveness of tirofiban for acute ischemic stroke without large or medium-sized vessel occlusion: A Markov modelling analysis from the Chinese and United States perspectives;PLOS ONE;2024-02-16

3. Tislelizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy as First-Line Treatment for Chinese Patients with Advanced Esophageal Squamous Cell Carcinoma: A Cost-Effectiveness Analysis;Clinical Drug Investigation;2023-08